All In Biotech

Free tool

FAERS Monitor: Kalbitor

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125277 or its brand name (Kalbitor, Ecallantide). Reports on generic versions are filed under their own applications.

Reports

1,869

Serious

1,138

61% of reports

Hospitalization

780

Death reported

34

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hereditary angioedema782
  • off label use170
  • drug ineffective147
  • malaise86
  • headache84
  • product dose omission issue72
  • pain70
  • hypersensitivity68
  • weight decreased68
  • nausea67
  • anaphylactic reaction62
  • weight increased60
  • therapeutic response decreased54
  • vomiting53
  • pneumonia52

Reports by year received

View as table
YearReports
20109
201120
201267
201370
2014197
2015333
2016499
201769
2018124
201986
202084
202178
202262
202338
202438
202564
202631

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,290 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hereditary angioedemaSignal782884.4835.4639,295
anaphylactic reactionSignal6212.69.9654
therapeutic response decreasedSignal5410.07.7431
hypersensitivitySignal684.13.3159
weight increasedSignal603.02.480
product dose omission issueSignal722.82.280
weight decreasedSignal682.72.274
malaiseSignal862.21.857
off label useSignal1702.21.9113
pneumonia521.81.418
headache841.51.214
pain701.31.04
vomiting531.31.03
drug ineffective1471.31.18
nausea671.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.